Table 4.
Mediating effect and proportions of metabolic factors, endocrine factors and inflammation biomarkers between mVOCs and the prevalence of sarcopenia.
| Pathways | Indirect effect | 95% CI | P-value | Mediation proportions | 95% CI | P-value |
|---|---|---|---|---|---|---|
| Metabolic factors | ||||||
| mVOCs → TG/HDL-C → sarcopenia | 0.000 | −0.001–0.00 | 0.28 | 0.2% | −0.022–0.002 | 0.28 |
| Endocrine factors | ||||||
| mVOCs → Vitamin D → sarcopenia | −0.003 | −0.006–0.00 | 0.04 | 4.6% | −0.11 to −0.001 | 0.04 |
| Inflammation factors | ||||||
| mVOCs → SII → sarcopenia | 0.001 | 0.00–0.003 | 0.01 | 1.9% | 0.004–0.051 | 0.01 |
| mVOCs → WBC → sarcopenia | 0.003 | 0.001–0.006 | 0.00 | 5.1% | 0.019–0.11 | 0.00 |
| mVOCs → ALP → sarcopenia | 0.005 | 0.003–0.009 | 0.00 | 8.5% | 0.045–0.15 | 0.00 |
The mVOCs were grouped based on the correlation matrix.
mVOCs, metabolites of volatile organic compounds; SII, Systemic Immune-Inflammation Index; WBC, White blood cell; ALP, Alkaline phosphatase; GroupPIP, group posterior inclusion probability; CondPIP, conditional posterior inclusion probability.